Cytochrome P450 regulation and drug biotransformation during inflammation and infection

被引:141
作者
Renton, KW [1 ]
机构
[1] Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 4H7, Canada
关键词
D O I
10.2174/1389200043335559
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The expression of cytochrome P450 and related biotransformation is altered during the operation of host defense mechanisms. This has major implications in inflammation and infection when the capacity of the liver and other organs to handle drugs is severely compromised. In most cases individual cytochrome P450 forms are down regulated at the level of gene transcription with a resulting decrease in the corresponding mRNA, protein and enzyme activity. The loss in drug metabolism is channeled predominantly through the production of cytokines which ultimately modify specific transcription factors. Other proposed mechanisms that apply to specific cytochrome P450s involve post translational steps including enzyme modification and increased degradation. When inflammatory responses are confined to the brain there is a loss of cytochrome P450 not only in the brain but also in peripheral tissues. This involves a yet to be identified mode of signaling between the brain and periphery but it does involve the production of cytokines from a peripheral source. In clinical medicine there are numerous examples of a decreased capacity to handle drugs during infections and disease states that involve an inflammatory component. This often results in altered drug responses and increased toxicities. Inflammation mediated alterations in the metabolism of endogenous compounds can lead to altered physiology. Changes in drug handling capacity during inflammation/injection will continue to be one of the many factors that complicate therapeutics.
引用
收藏
页码:235 / 243
页数:9
相关论文
共 122 条
[1]  
ANOLIK R, 1982, ANN ALLERGY, V49, P109
[2]   ALTERED DISTRIBUTION OF DEBRISOQUINE OXIDATION PHENOTYPES IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
BAER, AN ;
MCALLISTER, CB ;
WILKINSON, GR ;
WOOSLEY, RL ;
PINCUS, T .
ARTHRITIS AND RHEUMATISM, 1986, 29 (07) :843-850
[3]  
BARKER CW, 1992, J BIOL CHEM, V267, P8050
[4]   Effect of interferon α-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 N-acetyltransferase-2 activities in patients with chronic active hepatitis C [J].
Becquemont, L ;
Chazouilleres, O ;
Serfaty, L ;
Poirier, JM ;
Broly, F ;
Jaillon, P ;
Poupon, R ;
Funck-Brentano, C .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (06) :488-495
[5]   Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response [J].
Beigneux, AP ;
Moser, AH ;
Shigenaga, JK ;
Grunfeld, C ;
Feingold, KR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 293 (01) :145-149
[6]  
Beurton F, 1999, INT J MOL MED, V3, P33
[7]   Cytochrome P450 inactivation by serum from humans with a viral infection and serum from rabbits with a turpentine-induced inflammation: the role of cytokines [J].
Bleau, AM ;
Levitchi, MC ;
Maurice, H ;
du Souich, P .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (08) :1777-1784
[8]  
Bleau AM, 2001, DRUG METAB DISPOS, V29, P1007
[9]  
Brockmeyer NH, 1998, INT J CLIN PHARM TH, V36, P309
[10]   Comparative effects of cytokines on constitutive and inducible expression of the gene encoding for the cytochrome P450 3A6 isoenzyme in cultured rabbit hepatocytes:: Consequences on progesterone 6β-hydroxylation [J].
Calleja, C ;
Eeckhoutte, C ;
Dacasto, M ;
Larrieu, G ;
Dupuy, J ;
Pineau, T ;
Galtier, P .
BIOCHEMICAL PHARMACOLOGY, 1998, 56 (10) :1279-1285